Table 1. Clinical characteristics at... | American Society of Hematology

Table 1.

Clinical characteristics at diagnosis

Patient	Age, y	Sex	White blood cells, 10⁹/L	Hemoglobin, g/dL	Platelets, 10⁹/L	Blood monocytes, % (10⁹/L)		Bone marrow blasts, %	Circulating immature myeloid cells	WHO subtype	FAB subtype	Karyotype	Cytogenetic risk	Mutated genes
1	57	Male	29	13.6	97	29	8.4	18	No	CMML-2	Proliferative	46,XY[20]	Low	KRAS, SRSF2, TET2
2	73	Male	44.2	11.7	30	9	3.9	1	Yes	CMML-0	Proliferative	46,XY[20]	Low	CSF3R, TET2
3	68	Female	15.1	13.2	51	41	6.0	1	No	CMML-0	Proliferative	47,XX,+8[6]/46,XX[14]	High	TET2
4	80	Female	15.4	12.3	255	35	5.3	1.4	No	CMML-0	Proliferative	46,XX[20]	Low	PHF6, RUNX1, TET2, CBL
5	70	Male	62	12.1	132	22	13.0	18	Yes	CMML-2	Proliferative	46,XY[20]	Low	RUNX1, SRSF2, DNMT3A
6	61	Female	20	12.2	353	16	3.2	4	Yes	CMML-0	Proliferative	46,XX[20]	Low	ASXL1, SETBP1
7	67	Male	34	10.7	126	36	12.0	0	No	CMML-0	Dysplastic	46,XX[20]	Low	ASXL1, NRAS, RUNX1, TET2, ZRSR2
8	74	Male	17.3	11.2	21	38	6.5	19	Yes	CMML-2	Proliferative	45,XY,-7[3]/46,XY[20]	High	TET2, RUNX1, CBL
9	87	Male	8.4	8.2	652	46	3.8	NA*	Yes	NA*	Dysplastic	NA*	NA	NA
10	76	Male	3.3	10.5	126	38	1.2	2	No	CMML-0	Dysplastic	46,XY[20]	Low	TET2, CBL, CSF3R
11	72	Male	11.6	10.2	18	17	1.9	1	Yes	CMML-0	Dysplastic	46,XY[20]	Low	TET2, CSF3R, SRSF2
12	72	Male	5.2	13.6	87	24	1.2	3	Yes	CMML-0	Dysplastic	46,XY[20]	Low	TET2, RUNX, SRSF2

Patient	Age, y	Sex	White blood cells, 10⁹/L	Hemoglobin, g/dL	Platelets, 10⁹/L	Blood monocytes, % (10⁹/L)		Bone marrow blasts, %	Circulating immature myeloid cells	WHO subtype	FAB subtype	Karyotype	Cytogenetic risk	Mutated genes
1	57	Male	29	13.6	97	29	8.4	18	No	CMML-2	Proliferative	46,XY[20]	Low	KRAS, SRSF2, TET2
2	73	Male	44.2	11.7	30	9	3.9	1	Yes	CMML-0	Proliferative	46,XY[20]	Low	CSF3R, TET2
3	68	Female	15.1	13.2	51	41	6.0	1	No	CMML-0	Proliferative	47,XX,+8[6]/46,XX[14]	High	TET2
4	80	Female	15.4	12.3	255	35	5.3	1.4	No	CMML-0	Proliferative	46,XX[20]	Low	PHF6, RUNX1, TET2, CBL
5	70	Male	62	12.1	132	22	13.0	18	Yes	CMML-2	Proliferative	46,XY[20]	Low	RUNX1, SRSF2, DNMT3A
6	61	Female	20	12.2	353	16	3.2	4	Yes	CMML-0	Proliferative	46,XX[20]	Low	ASXL1, SETBP1
7	67	Male	34	10.7	126	36	12.0	0	No	CMML-0	Dysplastic	46,XX[20]	Low	ASXL1, NRAS, RUNX1, TET2, ZRSR2
8	74	Male	17.3	11.2	21	38	6.5	19	Yes	CMML-2	Proliferative	45,XY,-7[3]/46,XY[20]	High	TET2, RUNX1, CBL
9	87	Male	8.4	8.2	652	46	3.8	NA*	Yes	NA*	Dysplastic	NA*	NA	NA
10	76	Male	3.3	10.5	126	38	1.2	2	No	CMML-0	Dysplastic	46,XY[20]	Low	TET2, CBL, CSF3R
11	72	Male	11.6	10.2	18	17	1.9	1	Yes	CMML-0	Dysplastic	46,XY[20]	Low	TET2, CSF3R, SRSF2
12	72	Male	5.2	13.6	87	24	1.2	3	Yes	CMML-0	Dysplastic	46,XY[20]	Low	TET2, RUNX, SRSF2

FAB, French-American-British, NA, not available, WHO, World Health Organization.

No bone marrow biopsy and karyotype performed at diagnosis.